Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hemophilia

Hemophilia

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hemophilia

11 trials tracked for Hemophilia: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 43 citations.

11Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 3 Phase 1 1 Other / NA 7
  1. Phase 3 A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis Completed · 43 cited
  2. Phase 3 LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures Completed
  3. Phase 3 Prospective Biomarkers of Bone Metabolism in Hemophilia A Completed
  4. Phase 1 Viral Kinetics in HCV Clearance in Subjects With Hemophilia Completed
  5. N/A Patient Reported Outcomes Burdens and Experiences - Phase 2 Completed
  6. N/A Clinical Trial of Factor XIII (FXIII) Concentrate Completed
Show 5 more trials
  1. N/A Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy Completed
  2. N/A Study Evaluating Liver Transplantation in Haemophilia Patients in Spain Completed
  3. N/A Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy Completed
  4. N/A Low-Cost Platelet-Rich Plasma for Hemarthropathy Completed
  5. N/A A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Hemophilia: what the trials found

Fitusiran demonstrated a significant reduction in the Estimated Annualized Bleeding Rate (ABR) from 7.482 to 2.908 (p=0.0008) 1. Clinical assessments of quality of life using the Haem-A-QOL Physical Health Score and Total Score showed decreases of -6.00 and -3.07 respectively in the Fitusiran treatment period compared to -9.60 and -7.62 in the Factor or BPA prophylaxis period 1.

Advate was evaluated in a Phase 3 trial 2. Additionally, Recombinant Coagulation Factor VIIa (LR769) showed varying rates of 'Good' or 'Excellent' response to surgical or other invasive procedures, with success rates of 5%, 2%, 0%, and 0% across different assessment groups 3.

Recent results — preliminary, needs further review

  • Intra-articular PRP Injection showed a Foot and Ankle Outcome Score (FAOS) of 94.12 for function 5.

For the clinician treating this condition

  • Fitusiran significantly reduces the Estimated Annualized Bleeding Rate (ABR) in patients with Hemophilia 1.
  • Fitusiran treatment is associated with changes in physical health and total quality of life scores compared to standard Factor or BPA prophylaxis 1.
  • Recombinant Coagulation Factor VIIa (LR769) has been evaluated for its efficacy in surgical or invasive procedures 3.

AI synthesis of 4 cited trials, updated Sep 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.